Trial Profile
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Orelabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors InnoCare Pharma
- 08 Jul 2023 Results (from studies NCT03206918 and NCT03493217) assessing Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemiapublished in the Investigational New Drugs
- 13 Dec 2022 Samples of patients from this study were analyzed for orelabrutinib progression, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition